Key result
Taxanes cause dose-dependent neurotoxicity in cancer patients manageable with proven prevention and treatment methods.
Why the study?
The review addresses the specifics of taxanes' mechanism, classification, and clinical manifestations of neurotoxicity, including treatment and prevention methods.
What are the mechanisms, clinical manifestations, and management strategies for neurotoxicity caused by taxanes in cancer patients?
What are the mechanisms, clinical manifestations, and management strategies for neurotoxicity caused by taxanes in cancer patients?
This review provides a comprehensive overview of taxane-induced neurotoxicity, including its mechanisms, clinical features, and management strategies in cancer patients.
Supports monitoring for dose-dependent taxane neurotoxicity in cancer therapy; leaves open need for prospective trials on optimal strategies.
The review presents the data on the specifics of mechanism of action, classification, and clinical manifestations of neurotoxicity effect. The most significant features of specific side effects when using taxanes in different treatment regimens, including cumulative doses, are considered. The proven methods of treatment and prevention of neuropathy caused by anticancer drugs are discussed.
No takes yet. Share an insight, caveat, or question.
Tkachenko et al. (2021) studied this question. Taxane use in cancer patients causes neurotoxicity with specific clinical manifestations dependent on cumulative doses, which can be managed with proven prevention and treatment methods.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: